Insmed Incorporated (INSM) NASDAQ
103.73
-2.3(-2.17%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
103.73
-2.3(-2.17%)
Currency In USD
Address
700 US Highway 202/206
Bridgewater, NJ 08807
United States of America (the)
Phone
908 977 9900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1271
First IPO Date
June 01, 2000
| Name | Title | Pay | Year Born |
| William H. Lewis | President, Chief Executive Officer & Chairman | 2.47M | 1969 |
| Eugene J. Sullivan FCCP | Chief Product Strategy Officer | 593,080 | 1965 |
| S. Nicole Schaeffer | Chief People Strategy Officer | 660,810 | 1968 |
| Sara Bonstein | Chief Financial Officer | 1.12M | 1981 |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary | 1.14M | 1978 |
| Roger Adsett | Chief Operating Officer | 1.19M | 1969 |
| Martina Flammer | Chief Medical Officer | 1.22M | 1964 |
| Claire Mulhearn | Vice President of Corporate Communications | 0 | N/A |
| Kevin Mange | Chief Development Officer | 0 | N/A |
| Neil Hughes | GM & Head of Europe, Middle East and Africa | 0 | N/A |
| Adele Deering | Senior Vice President of Portfolio Strategy & Operational Excellence | 0 | N/A |
| Christie Camelio | Chief Compliance Officer | 0 | N/A |
| Brian K. Kaspar | Chief Scientific Officer | 0 | 1974 |
| Bryan Dunn | Vice President of Investor Relations | 0 | N/A |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.